Rilonacept

DB06372

biotech approved investigational

Deskripsi

Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 8.6 days
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1028 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Rilonacept.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Rilonacept.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Rilonacept.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Rilonacept.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Rilonacept.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Rilonacept.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Rilonacept.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Rilonacept.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Rilonacept.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rilonacept.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Rilonacept.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Rilonacept.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Rilonacept.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Rilonacept.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Rilonacept.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Rilonacept.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rilonacept.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Rilonacept.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rilonacept.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Rilonacept.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Rilonacept.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rilonacept.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Rilonacept.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Rilonacept.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Rilonacept.
Cladribine Rilonacept may increase the immunosuppressive activities of Cladribine.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Rilonacept.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Rilonacept.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Rilonacept.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Rilonacept.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Rilonacept.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Rilonacept.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Rilonacept.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Rilonacept.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Rilonacept.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Rilonacept.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Rilonacept.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Rilonacept.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Rilonacept.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Rilonacept.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Rilonacept.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Rilonacept.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Rilonacept.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Rilonacept.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Rilonacept.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Rilonacept.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Rilonacept.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Rilonacept.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Rilonacept.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Rilonacept.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Rilonacept.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Rilonacept.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Rilonacept.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Rilonacept.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Rilonacept.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Rilonacept.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rilonacept.
Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Rilonacept.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Rilonacept.
Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Rilonacept.
Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Rilonacept.
Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Rilonacept.
Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Rilonacept.
Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Rilonacept.
Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Rilonacept.
Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Rilonacept.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Rilonacept.
Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Rilonacept.
Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Rilonacept.
Abatacept The risk or severity of adverse effects can be increased when Abatacept is combined with Rilonacept.
Stepronin The risk or severity of adverse effects can be increased when Stepronin is combined with Rilonacept.
Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Rilonacept.
Vorinostat The risk or severity of adverse effects can be increased when Vorinostat is combined with Rilonacept.
2-Methoxyethanol The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Rilonacept.
Brequinar The risk or severity of adverse effects can be increased when Brequinar is combined with Rilonacept.
Interferon alfa The risk or severity of adverse effects can be increased when Interferon alfa is combined with Rilonacept.
Glatiramer The risk or severity of adverse effects can be increased when Glatiramer is combined with Rilonacept.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Rilonacept.
Human interferon omega-1 The risk or severity of adverse effects can be increased when Human interferon omega-1 is combined with Rilonacept.
Canakinumab The risk or severity of adverse effects can be increased when Canakinumab is combined with Rilonacept.
Tocilizumab The risk or severity of adverse effects can be increased when Tocilizumab is combined with Rilonacept.
Mepolizumab The risk or severity of adverse effects can be increased when Rilonacept is combined with Mepolizumab.
Abetimus The risk or severity of adverse effects can be increased when Rilonacept is combined with Abetimus.
Belatacept The risk or severity of adverse effects can be increased when Rilonacept is combined with Belatacept.
Pralatrexate The risk or severity of adverse effects can be increased when Rilonacept is combined with Pralatrexate.
Wortmannin The risk or severity of adverse effects can be increased when Rilonacept is combined with Wortmannin.
Eribulin The risk or severity of adverse effects can be increased when Rilonacept is combined with Eribulin.
Belimumab The risk or severity of adverse effects can be increased when Rilonacept is combined with Belimumab.
Teriflunomide The risk or severity of adverse effects can be increased when Rilonacept is combined with Teriflunomide.
Carfilzomib The risk or severity of adverse effects can be increased when Rilonacept is combined with Carfilzomib.
Dimethyl fumarate The risk or severity of adverse effects can be increased when Rilonacept is combined with Dimethyl fumarate.
Obinutuzumab The risk or severity of adverse effects can be increased when Rilonacept is combined with Obinutuzumab.
Secukinumab The risk or severity of adverse effects can be increased when Rilonacept is combined with Secukinumab.
Vedolizumab The risk or severity of adverse effects can be increased when Rilonacept is combined with Vedolizumab.
Siltuximab The risk or severity of adverse effects can be increased when Rilonacept is combined with Siltuximab.
Blinatumomab The risk or severity of adverse effects can be increased when Rilonacept is combined with Blinatumomab.
Dinutuximab The risk or severity of adverse effects can be increased when Rilonacept is combined with Dinutuximab.
Tixocortol The risk or severity of adverse effects can be increased when Rilonacept is combined with Tixocortol.
Peginterferon beta-1a The risk or severity of adverse effects can be increased when Rilonacept is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Rilonacept is combined with Antilymphocyte immunoglobulin (horse).

Target Protein

Interleukin-1 beta IL1B
Interleukin-1 alpha IL1A
Interleukin-1 receptor antagonist protein IL1RN

Referensi & Sumber

Synthesis reference: Rilonacept is expressed in recombinant Chinese hamster ovary (CHO) cells.
Artikel (PubMed)
  • PMID: 23031624
    Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y, Weinstein SP: Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther. 2012 Oct;34(10):2091-103. doi: 10.1016/j.clinthera.2012.09.009. Epub 2012 Sep 29.
  • PMID: 23553601
    Tran TH, Pham JT, Shafeeq H, Manigault KR, Arya V: Role of interleukin-1 inhibitors in the management of gout. Pharmacotherapy. 2013 Jul;33(7):744-53. doi: 10.1002/phar.1265. Epub 2013 Apr 3.
  • PMID: 12815153
    Hawkins PN, Lachmann HJ, McDermott MF: Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med. 2003 Jun 19;348(25):2583-4.
  • PMID: 23319019
    Cronstein BN, Sunkureddi P: Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. J Clin Rheumatol. 2013 Jan;19(1):19-29. doi: 10.1097/RHU.0b013e31827d8790.

Contoh Produk & Brand

Produk: 3 • International brands: 0
Produk
  • Arcalyst
    Injection, powder, lyophilized, for solution • 160 mg/2mL • Subcutaneous • US • Approved
  • Arcalyst
    Injection, powder, lyophilized, for solution • 160 mg/2mL • Subcutaneous • US • Approved
  • Rilonacept Regeneron
    Injection, powder, for solution • 80 mg/ml • Subcutaneous • EU

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul